135 related articles for article (PubMed ID: 21872826)
1. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.
Paquette RL; Nicoll J; Chalukya M; Elashoff D; Shah NP; Sawyers C; Spiteri E; Nanjangud G; Rao PN
Cancer Genet; 2011 Jul; 204(7):392-7. PubMed ID: 21872826
[TBL] [Abstract][Full Text] [Related]
2. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
3. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
4. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
5. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
6. EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22).
De Weer A; Poppe B; Cauwelier B; Carlier A; Dierick J; Verhasselt B; Philippé J; Van Roy N; Speleman F
BMC Cancer; 2008 Jul; 8():193. PubMed ID: 18613965
[TBL] [Abstract][Full Text] [Related]
7. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis].
Liu XP; Zhang MR; Dai Y; Zhang L; Li R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):310-3. PubMed ID: 16875579
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
9. EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia.
Ohyashiki K; Ohyashiki JH; Fujieda H; Shimamoto T; Kawakubo K; Nakazawa S; Suzukawa K; Morishita K; Toyama K
Leukemia; 1994 Dec; 8(12):2169-73. PubMed ID: 7808006
[TBL] [Abstract][Full Text] [Related]
10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
11. [ABL domain kinase point mutations as a cause of resistance to therapy of patients with chronic myeloid leukemia with tyrosine kinase inhibitors. Single center experience].
Sacha T; Foryciarz K; Florek I; Zawada M; Czekalska S; Cwynar D; Pecek E; Skotnicki AB
Przegl Lek; 2011; 68(5):253-7. PubMed ID: 21961412
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
13. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
14. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
15. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
[TBL] [Abstract][Full Text] [Related]
16. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
17. Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia.
Henzan H; Yoshimoto G; Okeda A; Nagasaki Y; Hirano G; Takase K; Tanimoto T; Miyamoto T; Fukuda T; Nagafuji K; Harada M
Ann Hematol; 2004 Dec; 83(12):784-8. PubMed ID: 15322764
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
19. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
20. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
